ESMO 2017 Immuno-OncologyVeröffentlicht am: 11. Sep. 2017
Bladder Cancer - Mature results favour pembrolizumab as second-line treatment
Results from the KEYNOTE-045 trial have confirmed longer survival in patients with advanced urothelial cancer who receive pembrolizumab.
